4-Nerolidylcatechol | 74683-11-7

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 异戊烯醇脂质
• 英文名称: 4-Nerolidylcatechol
• 英文别名: 4-[(6E)-3,7,11-trimethyldodeca-1,6,10-trien-3-yl]benzene-1,2-diol
• CAS: 74683-11-7
• 化学式: C₂₁H₃₀O₂
• 分子量: 314.5
• InChiKey: ZBZZDHDWRSFLAY-GZTJUZNOSA-N

物化性质

• 沸点：
  461.5±33.0 °C(Predicted)
• 密度：
  0.993±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  7
• 重原子数：
  23
• 可旋转键数：
  8
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  40.5
• 氢给体数：
  2
• 氢受体数：
  2

文献信息

• [EN] DERIVATIVES OF 4-NEROLIDYLCATECHOL, PHARMACEUTICAL COMPOSITIONS COMPRISING THEM AND PROCESS FOR PRODUCING THE SAME<br/>[FR] DÉRIVÉS DE 4-NÉROLIDYLCATÉCHOL, COMPOSITIONS PHARMACEUTIQUES COMPRENANT CES DÉRIVÉS ET PROCÉDÉ DE PRÉPARATION DE CEUX-CI
  申请人：INST NAC DE PESQUISA DA AMAZON

  公开号：WO2009082795A1

  公开（公告）日：2009-07-09

  The present invention discloses 4-nerolidylcatechol and its derivatives isolated from South American / Amazon plants (Pothomorphe species) and their potential use as therapeutical agent for treatment of malarial symptoms, including malarial patients resistant to traditional drugs. The present invention also discloses a method for producing 4-nerolidylcatechol and their derivatives.

  本发明公开了从南美/亚马逊植物（Pothomorphe物种）中分离出的4-nerolidylcatechol及其衍生物，以及它们作为治疗疟疾症状的治疗剂的潜在用途，包括对传统药物具有抗药性的疟疾患者。本发明还公开了一种生产4-nerolidylcatechol及其衍生物的方法。
• Oral dosage form
  申请人：Universiteit Gent

  公开号：US10966928B2

  公开（公告）日：2021-04-06

  The present invention in general relates to a pharmaceutical dosage form comprising one or more granules, and a method for manufacturing thereof. The granules of the dosage form are prepared via the extrusion/spheronization technique using partially hydrolysed polyvinyl alcohol. These granules have the advantage that a high drug load can be contained therein.

  本发明总体上涉及一种由一种或多种颗粒剂组成的药物剂型及其制造方法。该剂型的颗粒剂是使用部分水解的聚乙烯醇通过挤压/球化技术制备的。这种颗粒剂的优点是可以含有大量药物。
• Rapidly disintegrating oral dissolvable film
  申请人：CURE Pharmaceutical Holding Corp.

  公开号：US11344506B2

  公开（公告）日：2022-05-31

  The present invention provides for an oral dissolvable film that includes a rapidly dissolving binder, a film forming polymer, a moisture deterring polymer, and at least one of a first active ingredient and a second active ingredient. Also provided is a method of forming an oral dissolvable film and kits that include the oral dissolvable film. Also provided is a method of delivering one or more active ingredients to a subject that include orally administering the oral dissolvable film.

  本发明提供了一种口腔可溶解薄膜，它包括快速溶解粘合剂、成膜聚合物、防潮聚合物以及第一种活性成分和第二种活性成分中的至少一种。还提供了一种形成口服可溶膜的方法和包括口服可溶膜的试剂盒。还提供了一种向受试者提供一种或多种活性成分的方法，包括口服该口腔可溶膜。
• Use of pothomorphe umbellata extract, composition on basis of pothomorphe umbellata extract and method of application of the pothomorphe umbellata extract
  申请人：de Moraes Barros Berlanga Silvia

  公开号：US20060062858A1

  公开（公告）日：2006-03-23

  The present invention relates to the use of the Pothomorphe umbellata extract to prepare dermocosmetic and/or pharmaceutical compositions for the treatment and/or prevention of photodamage in the skin, cutaneous aging and/or skin cancer. It also refers to dermocosmetic and/or pharmaceutical compositions for treatment and/or prevention of such photodamage in the skin, cutaneous aging and/or skin cancer prepared on basis of the defined extract. In addition, it provides a method of application of the dermocosmetic and/or pharmaceutical compositions prepared on the basis of the extract of this plant, in way to treat and/or prevent the damage caused to the skin by the excessive exposure to ultraviolet rays of the sun and to artificial tanning lamps.

  本发明涉及使用 伞形百合花 提取物来制备治疗和/或预防皮肤光损伤、皮肤老化和/或皮肤癌的皮肤化妆品和/或药物组合物。本发明还涉及基于所定义的提取物制备的用于治疗和/或预防皮肤光损伤、皮肤老化和/或皮肤癌的皮肤化妆品和/或药物组合物。此外，它还提供了一种基于该植物提取物制备的皮肤化妆品和/或药物组合物的应用方法，以治疗和/或预防过度暴露于太阳紫外线和人造日光浴灯下对皮肤造成的损伤。
• USE OF POTHOMORPHE UMBELLATA EXTRACT, COMPOSITION ON BASIS OF POTHOMORPHE UMBELLATA EXTRACT AND METHOD OF APPLICATION OF THE POTHOMORPHE UMBELLATA EXTRACT
  申请人：Fundacao de Amparo a Pesquisa do Estado de Sao Paulo - FAPESP

  公开号：EP1578433A1

  公开（公告）日：2005-09-28